Sophie Mutel

Dr. Sophie Mutel


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
SMSophie Mutel
Sophie Mutel
LQLara Quatrocchi
Lara Quatrocchi
DADaniele Altomare
Daniele Altomare
CCChristian Chicherio
Christian Chicherio
MSMax Scheffler
Max Scheffler
FRFederica Ribaldi
Federica Ribaldi
INTRODUCTION: Resilience, the ability to maintain cognition or brain integrity despite Alzheimer's disease (AD) pathology, is often quantified using the residual approach. However, the variability in methodology and correction methods for this approach raises concerns about the interpretability of findings across studies.METHODS: We assessed brain resilience (BR) and cognitive resilience (CR) in a memory clinic population using the residual approach. We compared non‐corrected and corrected residuals’ associations with risk factors using linear regression models, and their impact on longitudinal cognition using linear mixed‐effects models.RESULTS: Corrected versus non‐corrected BR yielded distinct, often opposing, associations. For example, glial fibrillary acidic protein (GFAP) was negatively associated with non‐corrected BR (β = –0.33; p < 0.01) but positively with corrected BR (β = 0.5, p < 0.001). Only corrected CR measures yielded significant associations. Only corrected residuals predicted cognitive decline.DISCUSSION: The observed discrepancies raise questions about the reliability of the residual approach in accurately capturing resilience.Highlights: Corrected and non‐corrected residuals show distinct associations with risk factors. Corrected and non‐corrected residuals show different predictions of cognitive decline. These approaches may reflect general brain health rather than true resilience mechanisms.

Verified
Journal Article
Open access
PDF file
RMRoberta Mulargia
Roberta Mulargia
FRFederica Ribaldi
Federica Ribaldi
SMSophie Mutel
Sophie Mutel
OSOzge Sayin
Ozge Sayin
GKGiorgi Khachvani
Giorgi Khachvani
AMAugusto J. Mendes
Augusto J. Mendes
Dementia prevention is a global public health priority, and lifestyle interventions, including nutrition, have gained interest for their potential to maintain cognitive health. Among nutritional interventions, omega-3 polyunsaturated fatty acids (n-3 FA), particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been widely studied for their potential to support cognitive health. This systematic review evaluated whether n-3 FA supplementation improves global cognition in cognitively unimpaired older adults. Nineteen randomized controlled trials (RCTs) met inclusion criteria, of which five reported significant improvements in global cognition. A random-effects meta-analysis of 11 placebo-controlled RCTs showed no significant effect (SMD = −0.02, 95% CI: −0.07 to 0.04). Heterogeneity in supplement type, dosage, duration, and outcome measures may have contributed to inconsistent findings and limited comparability. Furthermore, methodological quality of the trials was generally low. While current evidence does not demonstrate a significant effect of n-3 FA supplementation on global cognition, future research should prioritize well-powered, longer-duration RCTs that incorporate biomarker monitoring and more appropriate doses. Clarifying the role of n-3 FA in cognitive aging remains essential for informing nutrition-based dementia prevention strategies.

14 August 2026 in Alzheimer's Research & Therapy
Verified
Journal Article
Open access
PDF file
SMSophie Mutel
Sophie Mutel
FRFederica Ribaldi
Federica Ribaldi
AMAugusto J. Mendes
Augusto J. Mendes
DADaniele Altomare
Daniele Altomare
CBCecilia Boccalini
Cecilia Boccalini
GFGiovanni B. Frisoni
Giovanni B. Frisoni
Background: Accurate detection of Alzheimer’s disease (AD) pathophysiological changes is crucial for research and clinical practice. While positron emission tomography (PET) imaging is an established reference standard for detecting brain amyloid and tau deposition, cerebrospinal fluid (CSF) biomarkers offer a more accessible alternative. This study aimed to identify optimal CSF biomarkers and thresholds for predicting tau and amyloid PET positivity in a memory clinic population. Methods: This cross-sectional, observational study included 220 participants from a memory clinic who underwent amyloid or tau PET scans and CSF biomarker analysis using either Fujirebio INNOTEST or LUMIPULSE assays. CSF biomarker performance was assessed via receiver operating characteristic (ROC) analysis. Double-threshold approaches were implemented to address classification uncertainty. Results: Ratios combining biomarkers of both amyloid and tau, such as Aβ42/pTau, consistently outperformed individual biomarkers in detecting amyloid and tau PET positivity. For amyloid PET, the Aβ42/pTau ratio achieved an AUC of 0.93 (95% CI: 0.86–0.99) with INNOTEST and an AUC of 0.89 (95% CI: 0.8–0.98) with LUMIPULSE. For tau PET, the Aβ42/pTau ratio achieved an AUC of 0.85 (95% CI: 0.77–0.93) with INNOTEST and an AUC of 0.97 (95% CI: 0.9-1.00) with LUMIPULSE. Double thresholds enabled classification based on predefined sensitivity and specificity, and can be used by clinicians to quickly assess a subject’s likelihood of positivity based on their biomarker levels. Discussion: CSF biomarker ratios such as Aβ42/pTau provide high predictive accuracy for brain amyloid and tau deposition. Implementing double thresholds enhances clinical utility by highlighting ambiguous cases requiring further assessment.